To assess the problem of user and methodological bias in quantification of ER expression in breast cancer, we chose a three-pronged experimental approach to compare both automated (Aperio) and visual ...
The question of when breast cancer is really estrogen receptor (ER) positive and endocrine responsive has troubled clinicians since the discovery of ER, but the issue is made even more acute by the ...
The QIF assay described in the article by Welsh et al 18 and developed by HistoRx (Branford, CT) became commercially available in late 2010 for clinical diagnostic use for ER, PgR, and HER2 testing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results